Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer

详细信息    查看全文

• 作者：C. Vanesa Díaz-García ; Alba Agudo-López ; Carlos Pérez ; Elena Prieto-García…
• 关键词：Non ; small cell lung cancer ; Dual ; specificity phosphatases ; Prognosis ; Survival
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：36
• 期：2
• 页码：1199-1206
• 全文大小：541 KB
• 参考文献：1. Siegel, R, Naishadham, D, Jemal, A (2013) Cancer statistics, 2013. CA Cancer J Clin.
  2. Ferlay, J, Steliarova-Foucher, E, Lortet-Tieulent, J, Rosso, S, Coebergh, JW, Comber, H (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer.
  3. Malvezzi, M, Bertuccio, P, Levi, F, Vecchia, C, Negri, E (2013) European cancer mortality predictions for the year 2013. Ann Oncol.
  4. O’Reilly, KE, Rojo, F, She, QB, Solit, D, Mills, GB, Smith, D (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.
  5. Shaw, AT, Meissner, A, Dowdle, JA, Crowley, D, Magendantz, M, Ouyang, C (2007) Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev.
  6. Zhang, Z, Kobayashi, S, Borczuk, AC, Leidner, RS, Laframboise, T, Levine, AD (2010) Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis.
  7. Ostman, A, Hellberg, C, Bohmer, FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer.
  8. Julien, SG, Dube, N, Hardy, S, Tremblay, ML (2011) Inside the human cancer tyrosine phosphatome. Nat Rev Cancer.
  9. Patterson, KI, Brummer, T, O’Brien, PM, Daly, RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J.
  10. Wong, VC, Chen, H, Ko, JM, Chan, KW, Chan, YP, Law, S (2013) Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer.
  11. Camps, M, Nichols, A, Gillieron, C, Antonsson, B, Muda, M, Chabert, C (1998) Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science.
  12. Liu, S, Sun, JP, Zhou, B, Zhang, ZY (2006) Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. Proc Natl Acad Sci U S A.
  13. Arkell, RS, Dickinson, RJ, Squires, M, Hayat, S, Keyse, SM, Cook, SJ (2008) DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell Signal.
  14. Keyse, SM (2008) Dual-specificity MAP, kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev.
  15. Jurek, A, Amagasaki, K, Gembarska, A, Heldin, CH, Lennartsson, J (2009) Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem.
  16. Pulido, R, Hooft van Huijsduijnen, R (2008) Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J.
  17. Marchetti, S, Gimond, C, Roux, D, Gothie, E, Pouyssegur, J, Pages, G (2004) Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. J Cell Physiol.
  18. Okudela, K, Yazawa, T, Woo, T, Sakaeda, M, Ishii, J, Mitsui, H (2009) Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol.
  19. Chen, HY, Yu, SL, Chen, CH, Chang, GC, Chen, CY, Yuan, A (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med.
  20. Sato, M, Vaughan, MB, Girard, L, Peyton, M, Lee, W, Shames, DS (2006) Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res.
  21. Furukawa, T, Sunamura, M, Motoi, F, Matsuno, S, Horii, A (2003) Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol.
  22. Xu, S, Furukawa, T, Kanai, N, Sunamura, M, Horii, A (2005) Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet.
  23. Chan, DW, Liu, VW, Tsao, GS, Yao, KM, Furukawa, T, Chan, KK (2008) Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis.
  24. Lee, JU, Huang, S, Lee, MH, Lee, SE, Ryu, MJ, Kim, SJ (2013) Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol.
  25. Zhang, H, Guo, Q, Wang, C, Yan, L, Fu, Y, Fan, M (2013) Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell. Mol Cell Endocrinol.
  26. Messina, S, Frati, L, Leonetti, C, Zuchegna, C, Zazzo, E, Calogero, A (2011) Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene.
  27. Arora, D, Kothe, S, Eijnden, M, Hooft van Huijsduijnen, R, Heidel, F, Fischer, T (2013) Expression of protein-tyrosine phosphatases in acute myeloid leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. Cell Commun Signal.
  28. Suwinski, R, Klusek, A, Tyszkiewicz, T, Kowalska, M, Szczesniak-Klusek, B, Gawkowska-Suwinska, M (2013) Gene
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Dual-specificity phosphatase 6 (DUSP6/MKP-3) is a mitogen-activated protein kinase phosphatase that regulates extracellular signal-regulated kinases (ERKs) activity via feedback mechanisms, with an increasingly recognized role in tumour biology. The aim of this study was to explore the role of DUSP6 expression in the prognosis of human non-small cell lung cancer (NSCLC). DUSP6 expression levels were evaluated by real-time quantitative reverse transcription polymerase chain reaction (PCR) in 60 NSCLC samples from patients who underwent pulmonary resection at 12 de Octubre University Hospital. We performed a statistical analysis to investigate the correlation of DUSP6 expression and the clinical outcomes. We found that 66.7?% of the tumour samples show the downregulation of DUSP6 at the messenger RNA (mRNA) levels compared to benign epithelial lung tissues and 55?% of them show at least twofold downregulation of DUSP6 gene expression. Patients were classified into three groups according to their DUSP6 expression levels and those with very low levels (at least twofold downregulation) had the worst outcomes. Using the value of twice below the mean value in benign epithelial lung tissue as a cutoff, the overall survival of patients with very low DUSP6 levels was significantly lower than that in the rest of patients (31.9?±-8.8?months vs. not reached, P--.049). This was most pronounced in adenocarcinoma histology and high-stage tumour samples. Our results suggest that DUSP6 gene expression in tumour samples may be a prognostic marker in NSCLC.